SYDNEY, AUSTRALIA: Artrya Limited, a company that develops artificial intelligence (AI) solutions for heart disease diagnosis and treatment, has announced its progress and goals for the next fiscal year. The company’s CEO, Mathew Regan, said he has focused on three key areas: launching Salix, its flagship product, in the US market; commercializing Salix in Australia…